JP2013523686A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523686A5 JP2013523686A5 JP2013501816A JP2013501816A JP2013523686A5 JP 2013523686 A5 JP2013523686 A5 JP 2013523686A5 JP 2013501816 A JP2013501816 A JP 2013501816A JP 2013501816 A JP2013501816 A JP 2013501816A JP 2013523686 A5 JP2013523686 A5 JP 2013523686A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine according
- polypeptide
- vaccine
- antigen
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 239000002245 particle Substances 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 241000224431 Entamoeba Species 0.000 claims 1
- 241000224466 Giardia Species 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 241000223785 Paramecium Species 0.000 claims 1
- 102400000368 Surface protein Human genes 0.000 claims 1
- 241000223892 Tetrahymena Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 238000002144 chemical decomposition reaction Methods 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10305317 | 2010-03-29 | ||
| EP10305317.9 | 2010-03-29 | ||
| PCT/EP2011/054866 WO2011120994A1 (en) | 2010-03-29 | 2011-03-29 | Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523686A JP2013523686A (ja) | 2013-06-17 |
| JP2013523686A5 true JP2013523686A5 (enExample) | 2014-05-15 |
| JP5942296B2 JP5942296B2 (ja) | 2016-06-29 |
Family
ID=42312972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501816A Expired - Fee Related JP5942296B2 (ja) | 2010-03-29 | 2011-03-29 | 少なくとも１つのｃｘｘｃモチーフを含むポリペプチドと異種抗原とを含む医薬組成物、及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9801927B2 (enExample) |
| EP (2) | EP3156068B1 (enExample) |
| JP (1) | JP5942296B2 (enExample) |
| KR (1) | KR101866301B1 (enExample) |
| CN (1) | CN103002909B (enExample) |
| AR (1) | AR081809A1 (enExample) |
| BR (1) | BR112012024872B1 (enExample) |
| CA (1) | CA2792174C (enExample) |
| ES (1) | ES2619077T3 (enExample) |
| SG (1) | SG183977A1 (enExample) |
| UY (1) | UY33297A (enExample) |
| WO (1) | WO2011120994A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2476436T3 (pl) | 2006-08-11 | 2018-05-30 | Life Sciences Research Partners Vzw | Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych |
| EP2623115A1 (en) | 2008-02-14 | 2013-08-07 | Life Sciences Research Partners VZW | Immunogenic control of tumours and tumour cells |
| EP3075391A1 (en) * | 2008-02-14 | 2016-10-05 | Life Sciences Research Partners VZW | Strategies to prevent and/or treat immune responses to soluble allofactors |
| EP2623125A1 (en) | 2008-02-14 | 2013-08-07 | Life Sciences Research Partners VZW | Elimination of immune responses to viral vectors |
| CA2715517C (en) * | 2008-02-14 | 2018-07-24 | Life Sciences Research Partners Vzw | Immunogenic peptides and their use in preventing or treating allograft rejection |
| ES2637812T3 (es) | 2008-02-14 | 2017-10-17 | Life Sciences Research Partners Vzw | Inmunoterapia dirigida a patógenos intracelulares |
| BR112013012555B8 (pt) | 2010-11-25 | 2022-09-06 | Imnate Sarl | Peptídeo imunogênico isolado derivado de uma proteína antigênica, seus usos, método para a preparação de um peptídeo com capacidade de provocar a ativação de células nkt e método in vitro para obtenção de uma população de células nkt cd4+ antígeno específicas |
| GB201201511D0 (en) | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
| US9457096B2 (en) * | 2012-07-06 | 2016-10-04 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) | Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery |
| JP2014212722A (ja) * | 2013-04-24 | 2014-11-17 | 学校法人加計学園 | 八面体構造を有するｂ型肝炎ウイルス様粒子結晶 |
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
| US10729791B2 (en) * | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
| AU2016328582B2 (en) | 2015-09-25 | 2022-11-24 | Imcyse Sa | Improved methods and compounds for eliminating immune responses to therapeutic agents |
| JP7320947B2 (ja) | 2016-04-19 | 2023-08-04 | アンシス・エスア | 新規な免疫原性ＣＤ１ｄ結合ペプチド |
| MY192295A (en) | 2017-03-09 | 2022-08-17 | Imcyse Sa | Peptides and methods for the treatment of diabetes |
| EP4144752A1 (en) * | 2021-09-02 | 2023-03-08 | Sorbonne Universite | Viral-like particles for the treatment or prevention of an infection by a coronaviridae virus |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6165469A (en) * | 1988-01-13 | 2000-12-26 | University Of Virginia | Recombinant Entamoeba histolytica lectin subunit peptides and reagents specific for members of the 170 kD subunit multigene family |
| MXPA01009256A (es) * | 1999-03-12 | 2003-07-14 | Aventis Pasteur | Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos. |
| EP1201750A1 (en) | 2000-10-26 | 2002-05-02 | Genopoietic | Synthetic viruses and uses thereof |
| BR0312297A (pt) | 2002-07-18 | 2005-04-12 | Cytos Biotechnology Ag | Conjugados veìculos de hapteno e seu uso |
| US7943396B2 (en) * | 2004-06-22 | 2011-05-17 | The Regents Of The University Of California | Peptide-coated nanoparticles with graded shell compositions |
| DE502004010408D1 (de) | 2004-07-02 | 2009-12-31 | Schoelly Fiberoptic Gmbh | Vorrichtung und verwendung der vorrichtung zur aufnahme und verarbeitung eines bildes |
| WO2006026746A2 (en) | 2004-08-31 | 2006-03-09 | The Government Of United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods to separate and expand antigen-specific t cells |
| GB0426641D0 (en) * | 2004-12-03 | 2005-01-05 | Bioactive Protein Delivery The | Protein delivery system |
| WO2007122388A2 (en) | 2006-04-13 | 2007-11-01 | Midatech Limited | Nanoparticles containing three various ligands for providing immune responses against infectious agents |
| AU2007345768B2 (en) * | 2006-07-27 | 2013-08-01 | Ligocyte Pharmaceuticals, Inc. | Chimeric influenza virus-like particles |
| PL2476436T3 (pl) * | 2006-08-11 | 2018-05-30 | Life Sciences Research Partners Vzw | Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych |
| EP2199301A1 (en) * | 2008-12-19 | 2010-06-23 | DKFZ Deutsches Krebsforschungszentrum | Immunogenic polypeptides comprising a scaffold polypeptide and a L2 polypeptide or fragment thereof |
-
2011
- 2011-03-29 JP JP2013501816A patent/JP5942296B2/ja not_active Expired - Fee Related
- 2011-03-29 EP EP16002285.1A patent/EP3156068B1/en active Active
- 2011-03-29 CA CA2792174A patent/CA2792174C/en active Active
- 2011-03-29 AR ARP110101036A patent/AR081809A1/es not_active Application Discontinuation
- 2011-03-29 CN CN201180017201.7A patent/CN103002909B/zh not_active Expired - Fee Related
- 2011-03-29 EP EP11710794.6A patent/EP2552476B1/en active Active
- 2011-03-29 BR BR112012024872-3A patent/BR112012024872B1/pt active IP Right Grant
- 2011-03-29 WO PCT/EP2011/054866 patent/WO2011120994A1/en not_active Ceased
- 2011-03-29 KR KR1020127028358A patent/KR101866301B1/ko not_active Expired - Fee Related
- 2011-03-29 UY UY0001033297A patent/UY33297A/es active IP Right Grant
- 2011-03-29 ES ES11710794.6T patent/ES2619077T3/es active Active
- 2011-03-29 SG SG2012066791A patent/SG183977A1/en unknown
- 2011-03-29 US US13/636,482 patent/US9801927B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523686A5 (enExample) | ||
| Medhi et al. | Nanoparticle-based strategies to combat COVID-19 | |
| Syomin et al. | Virus-like particles as an instrument of vaccine production | |
| US12472244B2 (en) | Immunogenic compositions and uses thereof | |
| Huang et al. | Escherichia coli-derived virus-like particles in vaccine development | |
| Yan et al. | The application of virus-like particles as vaccines and biological vehicles | |
| Lei et al. | Bioinspired cell silicification: from extracellular to intracellular | |
| Prange | Host factors involved in hepatitis B virus maturation, assembly, and egress | |
| SG165378A1 (en) | Functional influenza virus-like particles (vlps) | |
| Singh et al. | Insights from nanotechnology in COVID-19: prevention, detection, therapy and immunomodulation | |
| EP2361930A3 (en) | Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases | |
| JP2016519933A5 (enExample) | ||
| Zhou et al. | Vaccine strategies for human papillomavirus-associated head and neck cancers | |
| JP2012010713A5 (enExample) | ||
| JP2019513005A5 (enExample) | ||
| JP2018532382A5 (enExample) | ||
| MX375379B (es) | Receptores de celulas t anti - papilomavirus 16 e7 humano. | |
| EP3199545A3 (en) | Computationally optimized broadly reactive antigens for h1n1 influenza | |
| JP2015524422A5 (enExample) | ||
| JP2010522208A5 (enExample) | ||
| JP2016539641A5 (enExample) | ||
| JP2019536426A5 (enExample) | ||
| He et al. | Hepatitis virus capsid polymorph stability depends on encapsulated cargo size | |
| Chhikara et al. | Viral infection mitigations using advanced nanomaterials and tools: lessons from SARS-CoV-2 for future prospective interventions | |
| Alhashimi et al. | Nonhuman adenoviral vector-based platforms and their utility in designing next generation of vaccines for infectious diseases |